USE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR IS ASSOCIATED WITH LOW RISK OF HEPATIC DECOMPENSATIONS BUT IS NOT AFFECTING DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN TYPE II DIABETES PATIENTS.

被引：0
|
作者：
Kim, Heaeun [1 ]
Kim, Jin-Wook [1 ]
Park, Jaewon [1 ]
Jang, Sangmi [2 ]
Jeong, Chan Young [1 ]
Choi, Gwang Hyeon [1 ]
Jang, Eun Sun [1 ]
Jeong, Sook-Hyang [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1895
引用
收藏
页码：1127A / 1128A
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of sodium-glucose co-transporter-2 inhibitors in patients with kidney transplantation and diabetes mellitus
    Yeggalam, Aparna
    Liebich, Jessica Ann
    Yu, Kevin
    Shrestha, Ekta
    Nadella, Srikanth
    Ahir, Vaishaliben
    Newman, Jennifer
    Lentine, Krista L.
    Caliskan, Yasar
    Abu Al Rub, Fadee
    Dhindsa, Sandeep
    Albert, Stewart G.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1777 - 1780
  • [42] Current understanding of the effect of sodium-glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus
    Watada, Hirotaka
    DIABETOLOGY INTERNATIONAL, 2020, 11 (03) : 242 - 244
  • [43] Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
    Fatima, Tehreem
    Sedrakyan, Surik
    Awan, Muhammad R.
    Khatun, Mst. Khaleda
    Rana, Dibyata
    Jahan, Nusrat
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (08)
  • [44] A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care
    Taverner, Sofia
    Eng, Cindy
    Watson, Rebecca
    George, Siba
    Edwards, Amanda
    Williams, David M.
    Stephens, Jeffrey W.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (12)
  • [45] Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes
    Tang, Huilin
    Yang, Keming
    Song, Yiqing
    Han, Jiali
    DIABETES OBESITY & METABOLISM, 2018, 20 (12): : 2919 - 2924
  • [46] Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study
    Kim, Young-Gun
    Jeon, Ja Young
    Han, Seung Jin
    Kim, Dae Jung
    Lee, Kwan-Woo
    Kim, Hae Jin
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1852 - 1858
  • [47] Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report
    Trapanese, Vincenzo
    Maruca, Francesco
    Natale, Maria Resilde
    Giofre, Federica
    Cosentino, Francesca
    Sergi, Silvia
    Armentaro, Giuseppe
    Condoleo, Valentino
    Arturi, Franco
    ITALIAN JOURNAL OF MEDICINE, 2024, 18 (02)
  • [48] Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
    Park, Sohee
    Jeong, Han Eol
    Bea, Sungho
    Yu, Oriana H. Y.
    Cho, Young Min
    You, Seng Chan
    Man, Kenneth K. C.
    Shin, Ju-Young
    DIABETES OBESITY & METABOLISM, 2023, 25 (11): : 3248 - 3258
  • [49] Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, inChinesepeople with type 2 diabetes mellitus
    Li, Xiaojiao
    Zhu, Xiaoxue
    Liu, Jingrui
    Li, Qianqian
    Zhang, Hong
    Li, Cuiyun
    Wu, Min
    Gao, Lei
    Wen, He
    Li, Xixi
    Tang, Xinran
    Liu, Li
    Ding, Yanhua
    DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2316 - 2324
  • [50] Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases
    Gangat, Naseema
    Abdallah, Mostafa
    Szuber, Natasha
    Saliba, Antoine
    Alkhateeb, Hassan
    Al-Kali, Aref
    Begna, Kebede H.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : E165 - E167
12345